All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Tapan Kadia, MD Anderson Cancer Center, Houston, US. We asked, Is venetoclax combined with low-dose chemo and hypomethylating agent (HMA) safe and efficacious in older patients with AML?
Is venetoclax combined with low-dose chemo and HMA safe and efficacious in older patients with AML?
Older and unfit patients with AML represent a difficult-to-treat population. In these patients, low-intensity therapy has been used for years because of the risk of toxicities and high rates of early mortality often observed with intensive chemotherapy. Unfortunately, although the low-intensity regimen is better tolerated, the response rates are modest. Recently, it has been shown that venetoclax, a BCL-2 inhibitor, in addition to HMAs improves response rates over HMAs alone. In this video, Kadia reports the promising results of a clinical trial evaluating the addition of venetoclax to the low-intensity backbone of cladribine plus low-dose cytarabine alternating with 5-azacytidine in older or unfit patients with newly diagnosed AML.
Andrew Wei | ISAL 2019 | Targeting cell survival in AML
Andrew Wei discusses venetoclax in the context of targeting cell survival in AML at the 17th annual Acute Leukemias Meeting
Venetoclax in combination with hypomethylating agents for the treatment of older patients with NPM1-mutated acute myeloid leukemia
Approximately 30% of patients with acute myeloid leukemia (AML) have nucleophosmin-1 mutations (NPM1+), which are...
Subscribe to get the best content related to AML delivered to your inbox